RedHill Biopharma (RDHL) Cash from Financing Activities (2012 - 2022)

RedHill Biopharma (RDHL) has reported Cash from Financing Activities for 11 consecutive years, with $7.2 million the latest figure, recorded in Q4 2022.

• In Q4 2022, Cash from Financing Activities fell 59.02% year-over-year to $7.2 million; the TTM figure through Dec 2022 stood at $11.5 million (down 84.41% YoY), while the FY2025 annual figure was $7.3 million, down 13.07% from the prior year.
• Cash from Financing Activities climbed to $7.2 million in Q4 2022 per RDHL's latest filing, from -$5.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $59.1 million in Q1 2020 and bottomed at -$5.7 million in Q3 2022.
• Historically, Cash from Financing Activities has averaged $13.0 million across 5 years, with a median of $7.2 million in 2022.
• Annual changes were most pronounced in 2018 — Cash from Financing Activities surged 78406.67% — and 2022, when it tumbled 472.67%.
• RedHill Biopharma's Cash from Financing Activities stood at $18.4 million in 2018, then surged by 96.67% to $36.1 million in 2019, then tumbled by 78.0% to $7.9 million in 2020, then surged by 121.25% to $17.6 million in 2021, then slumped by 59.02% to $7.2 million in 2022.
• Business Quant data shows RDHL's Cash from Financing Activities at $7.2 million in Q4 2022, -$5.7 million in Q3 2022, and $14.9 million in Q2 2022.